Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.60 |
| ▸ | MAOA | P21397 | 10/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | AGER | Q15109 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878902 | 0.88 | CA12 (0.56) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL2129509 | 0.80 | MAOA (0.66) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL19645161 | 0.77 | MAOA (0.59) | MAOBMAOAHPGDALDH1A1CA2 | |
| SCHEMBL3567204 | 0.77 | MAOA (0.60) | MAOBMAOAAGERHPGDALDH1A1 | |
| SCHEMBL3122335 | 0.75 | MAOB (1.00) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL3802319 | 0.74 | MAOA (0.58) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL5878695 | 0.74 | ALDH1A1 (0.47) | MAOBMAOACA12CA1CA9 | |
| 7-Allyloxycoumarin SCHEMBL4765530 | 0.73 | CA12 (1.00) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL7901046 | 0.72 | MAOB (0.70) | MAOBMAOACA12CA1CA9 | |
| SCHEMBL2130280 | 0.71 | MAOA (0.55) | MAOBMAOAHPGDALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| EP-0309953-A1 | 5-Substituted-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methyl-isoxazolidines | FISONS CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4754042-A | 5-{[naphthyl(or 2-oxo-1,3-benzoxathiol-6-yl)oxy]methyl}-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | PENNWALT CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | MAOB 410/4885MAOA 428/4885CA12 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.